Treatment of Good Prognosis, BCL-6 Negative Diffuse Large Cell Lymphoma With CHOP-R in Patients < 61 Years Old.

• Register: ClinicalTrials.gov
• Last refreshed on: 17 October 2012
• Main ID: NCT00429065
• Date of registration: 30/01/2007
• Primary sponsor: Instituto Nacional de Cancerologia de Mexico
• Public title: Treatment of Good Prognosis, BCL-6 Negative Diffuse Large Cell Lymphoma With CHOP-R in Patients < 61 Years Old.
• Scientific title: Selection of Young Patients (< 61 Years), With Good Prognosis Diffuse Large B Cell Lymphoma, According to the Immunophenotype (BCL-6 Negative) to be Treated With Chemoimmunotherapy, With R-CHOP. A Pilot Study.
• Date of first enrolment: January 2007
• Target sample size: 30
• Recruitment status: Recruiting
• URL: http://clinicaltrials.gov/show/NCT00429065
• Study type: Observational
• Study design: Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Longitudinal, Time Perspective: Prospective

Countries of recruitment

Mexico

Contacts

• Name: Silvia Rivas-Vera, MD

• Name: Pedro Sobrevilla-Calvo, MD
• Affiliation: Instituto Nacional de Cancerologia Mexico

• Name: Silvia Rivas-Vera, MD
• Affiliation: Instituto Nacional de Cancerologia Mexico

Key inclusion & exclusion criteria

Inclusion Criteria:

- Diagnosis of Large B cell Non-Hodgkin Lymphoma CD20+

- BCL-6 negative

- Age < 61 years old

- ECOG 2 or less

- IPI low, low intermediate

- Stage II, III or IV

- Signed Informed Consent

Exclusion Criteria:

- Stage I

- Previous treatment

- Lymphomatous central nervous system involvement

- Heart disease

- Kidney failure (serum creatinine > 2 mg/dl)

- HIV +

- Viral Hepatitis

- Pregnancy



Age minimum: 15 Years
Age maximum: 60 Years
Gender: Both

Health Condition(s) or Problem(s) studied

Non-Hodgkin Lymphoma

Intervention(s)

Drug: Rituximab

Secondary ID(s)

Hemato INCAN 01/2007

Source(s) of Monetary Support

Please refer to primary and secondary sponsors